$BLCO News

Bausch + Lomb (BLCO) Stock Looks Cheap After Its 13% Gain

Did CEO Exit Just Shift Bausch + Lomb (BLCO) Investment Narrative?

Bausch + Lomb (BLCO) Resets Leadership As Its Undervalued Narrative Faces A New Test

Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up

Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up

3 Reasons BLCO is Risky and 1 Stock to Buy Instead

Why Is Bausch + Lomb Stock Falling Monday?

Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D

Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026

Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed Adulterated

BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

Leerink Partners Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $24

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers